It has been suggested that short-term intensive therapy with CSII in T2DM can relieve glucotoxicity, protect the function of the remaining islet β-cells, and contribute to long-term blood glucose control, and is an important means of intensive insulin therapy9. Here, INS is linked to type 2 diabetes mellitus.